MarketCapExport financials
Happiness Biotech Group Limited (HAPP)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Happiness Biotech Group Limited Balance Sheet 2026-2011 | HAPP
Brief overview of Happiness Biotech Group Limited's financial position
The comparison uses five available annual reports from the 2021–2025 interval.
Assets fell from $112.7 million to $35.6 million. This may reflect either deliberate optimization or a reduction in business scale.
Liabilities expanded faster than the asset base, -56.6% versus -68.5%. Debt-service capacity deserves attention.
Internal capital represents 68.2% of the balance sheet, previously 84%. This is a strong capital position.
Cash represents 0.7% of assets versus 32.4% initially, showing how the immediate liquidity reserve changed.
The accumulated result is -$70.3 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
Balance sheet takeaway
Happiness Biotech Group Limited's balance sheet looks stretched: reliance on liabilities and a limited capital cushion increase sensitivity to weaker results.
Annual Balance Sheet Happiness Biotech Group Limited
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-10.1 M | - | - | - | - | - | - | - | -7.39 M | -2.32 M | - | - | - | - | - | - |
Long Term Debt |
82.2 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
155 K | 102 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
1.38 M | 158 K | - | 1.51 M | - | - | - | - | - | 209 K | - | - | - | - | - | - |
Total Current Liabilities |
2.47 M | 6.4 M | 2.56 M | 21 M | 17.9 M | 15.1 M | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
3.86 M | 6.56 M | 2.56 M | 22.5 M | 20 M | 15.1 M | 5.51 M | 4.76 M | 8.84 M | 18.2 M | - | - | - | - | - | - |
Retained Earnings |
-83 M | -70.3 M | -62 M | -59.5 M | 12.3 M | 61.5 M | 68.7 M | 56 M | 35.3 M | 17.8 M | - | - | - | - | - | - |
Total Assets |
36.9 M | 35.6 M | 7.73 M | 36.3 M | 97.4 M | 113 M | 85.1 M | 65.7 M | 53.4 M | 41.5 M | - | - | - | - | - | - |
Cash and Cash Equivalents |
10.3 M | 261 K | 342 K | 3.36 M | 19.7 M | 36.6 M | 33.7 M | 14.8 M | 8.88 M | - | - | - | - | - | - | - |
Book Value |
33 M | 29 M | 5.17 M | 13.9 M | 77.4 M | 97.6 M | 79.6 M | 60.9 M | 44.6 M | 23.3 M | - | - | - | - | - | - |
Total Shareholders Equity |
31.2 M | 24.3 M | 5.58 M | 14.8 M | 78.1 M | 94.7 M | 79.6 M | 60.9 M | 44.6 M | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Happiness Biotech Group Limited
| 2026-Q4 | 2026-Q2 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | 190 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
158 K | 353 K | 158 K | 158 K | - | - | - | 1.51 M | 1.51 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
6.56 M | 8.85 M | 3.45 M | 6.56 M | 2.56 M | 2.56 M | 20 M | 493 K | 22.5 M | - | - | - | - | - | - | - | 15.1 M | - | 5.88 M | - | 5.51 M | - | - | - | 4.76 M | - | - | - | 8.84 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-70.3 M | -70.9 M | -64.1 M | -70.3 M | -62 M | -62 M | 12.3 M | -51.3 M | -59.5 M | - | - | - | - | - | - | - | 61.5 M | - | 69.4 M | - | 66.6 M | - | - | - | 53.9 M | - | - | - | 35.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
35.6 M | 37.3 M | 33.4 M | 35.6 M | 7.73 M | 7.73 M | 97.4 M | 11.2 M | 36.3 M | - | - | - | - | - | - | - | 113 M | - | 93.6 M | - | 85.1 M | - | - | - | 65.7 M | - | - | - | 53.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
3.36 M | 412 K | 105 K | 261 K | 19.7 M | 342 K | 19.7 M | 1.04 M | 3.36 M | - | - | - | - | - | - | - | 36.6 M | - | 43.8 M | - | 33.7 M | - | 23.8 M | - | 14.8 M | - | - | - | 8.88 M | - | - | - | 4.27 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
29 M | 28.4 M | 30 M | 29 M | 5.17 M | 5.17 M | 77.4 M | 10.7 M | 13.9 M | - | - | - | - | - | - | - | 97.6 M | - | 87.7 M | - | 79.6 M | - | - | - | 60.9 M | - | - | - | 44.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
13.9 M | 23.6 M | 30 M | 24.3 M | 77.4 M | 5.58 M | 79.6 M | 10.7 M | 14.8 M | - | - | - | - | - | - | - | 94.7 M | - | 87.6 M | - | 79.6 M | - | 66.2 M | - | 60.9 M | - | - | - | 44.6 M | - | - | - | 23.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Happiness Biotech Group Limited, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
Niderland
France
Israel
Australia
Schweiz
China
Britain
Irlanda
